Patents Assigned to Octapharma AG
-
Patent number: 11738069Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.Type: GrantFiled: May 21, 2021Date of Patent: August 29, 2023Assignee: OCTAPHARMA AGInventors: Christoph Kannicht, Stefan Winge, Guido Kohla, Barbara Solecka-Witulska
-
Patent number: 11713458Abstract: The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.Type: GrantFiled: June 20, 2017Date of Patent: August 1, 2023Assignee: Octapharma AGInventors: Karina Nawrath, Janine Guendel, Sven Bahrke, Lars Stoeckl, Steffen Goletz
-
Publication number: 20220305089Abstract: The invention relates to a pharmaceutical composition comprising an isolated Factor VIII protein and/or an isolated VWF protein in a stabilizing buffer composition, wherein said pharmaceutical composition is free of albumin and said stabilizing buffer 5 composition comprises cryoprotectants and bulking agents in a weight ratio of more than 0.65:1. The invention relates further relates to the use of a stabilizing buffer formulating an FVIII protein and/or a VWF protein to the use of a VWF protein for stabilizing a FVIII protein in vitro.Type: ApplicationFiled: August 14, 2020Publication date: September 29, 2022Applicant: OCTAPHARMA AGInventors: Ronny SCHMIDT, Tilo SCHWIENTEK
-
Patent number: 11401300Abstract: A process for purifying fibrinogen from a fibrinogen containing source by precipitation of fibrinogen by a precipitating agent from a fibrinogen containing solution in the presence of one or more chelating agent(s) and removal of the supernatant from the fibrinogen paste, characterised in that fibrinogen is extracted from the paste forming a liquid fraction containing fibrinogen, and an undissolved residue, which is separated from the liquid.Type: GrantFiled: September 19, 2018Date of Patent: August 2, 2022Assignee: OCTAPHARMA AGInventors: Petra Schulz, Werner Gehringer, Friedrich Schön, Caroline Leitinger, Jürgen Römisch, Rainer Pape
-
Patent number: 11383001Abstract: The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.Type: GrantFiled: May 31, 2017Date of Patent: July 12, 2022Assignee: OCTAPHARMA AGInventor: Daniel Grant Ericson
-
Patent number: 11383002Abstract: The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.Type: GrantFiled: September 25, 2020Date of Patent: July 12, 2022Assignee: OCTAPHARMA AGInventor: Daniel Grant Ericson
-
Patent number: 11191833Abstract: The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.Type: GrantFiled: June 12, 2017Date of Patent: December 7, 2021Assignee: OCTAPHARMA AGInventors: Karin Ahrer, Waltraud Kaar, Ulrich Roessl
-
Publication number: 20210290738Abstract: The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.Type: ApplicationFiled: July 8, 2019Publication date: September 23, 2021Applicant: OCTAPHARMA AGInventors: Juergen Roland ROEMISCH, Katharina POCK, Petra SCHULZ, Silvio WUSCHKO, Michael ANDESNER, Andrej MURANYI
-
Publication number: 20210275644Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.Type: ApplicationFiled: May 21, 2021Publication date: September 9, 2021Applicant: OCTAPHARMA AGInventors: Christoph KANNICHT, Stefan WINGE, Guido KOHLA, Barbara SOLECKA-WITULSKA
-
Patent number: 11013789Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.Type: GrantFiled: May 22, 2017Date of Patent: May 25, 2021Assignee: OCTAPHARMA AGInventors: Christoph Kannicht, Stefan Winge, Guido Kohla, Barbara Solecka-Witulska
-
Publication number: 20210008243Abstract: The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.Type: ApplicationFiled: September 25, 2020Publication date: January 14, 2021Applicant: OCTAPHARMA AGInventor: Daniel Grant ERICSON
-
Patent number: 10889630Abstract: The invention provides a method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps: contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin, and a complex of the FVIII protein and the vWF protein.Type: GrantFiled: February 10, 2017Date of Patent: January 12, 2021Assignee: OCTAPHARMA AGInventors: Stefan Winge, Per Rosen, Alex Scheepers
-
Patent number: 10822393Abstract: A process for manufacturing of a Factor VIII product having a ratio of FVIII:C/FVIII:Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. An anionic chromatography resin. A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98% for treatment of haemophilia and avoiding formation of inhibitors.Type: GrantFiled: January 20, 2015Date of Patent: November 3, 2020Assignee: OCTAPHARMA AGInventors: Stefan Winge, Marina Dadaian, Erica Johansson, Birte Fuchs
-
Publication number: 20200297893Abstract: The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.Type: ApplicationFiled: May 31, 2017Publication date: September 24, 2020Applicant: OCTAPHARMA AGInventor: Daniel Grant ERICSON
-
Patent number: 10640548Abstract: A method for inactivation or removal of coagulation factors FII, FVII, FVIIa, FIX, FIXa, FX, FXI and FXIa in or from protein containing solutions obtained from blood, blood plasma, plasma fractions or by recombinant means wherein the protein containing solution is contacted with an organic acid or its salt while being stirred.Type: GrantFiled: November 6, 2017Date of Patent: May 5, 2020Assignee: Octapharma AGInventors: Waltraud Kaar, Alfred Zochling, Karin Ahrer
-
Patent number: 10626431Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.Type: GrantFiled: June 30, 2016Date of Patent: April 21, 2020Assignee: OCTAPHARMA AGInventor: Stefan Winge
-
Publication number: 20200069780Abstract: The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.Type: ApplicationFiled: May 16, 2018Publication date: March 5, 2020Applicant: OCTAPHARMA AGInventors: Georg LATTNER, Klaus TSCHETSCHKOWITSCH, Almira DUGIC
-
Publication number: 20190358301Abstract: A histidine-free composition comprising: a high purity factor VIII (r-factor VIII); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor VIII; an amount of calcium chloride for specific stabilization of factor VIII.Type: ApplicationFiled: December 20, 2018Publication date: November 28, 2019Applicant: OCTAPHARMA AGInventors: Brita Rippner, Josefin Knutsson, Ulrika Nilsson, Elsa Ivarsson, Irène Agerkvist
-
Publication number: 20190201495Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.Type: ApplicationFiled: May 22, 2017Publication date: July 4, 2019Applicant: OCTAPHARMA AGInventors: Christoph KANNICHT, Stefan WINGE, Guido KOHLA, Barbara SOLECKA-WITULSKA
-
Publication number: 20190169268Abstract: The invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and said extension peptide comprises a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of the mammalian protein and/or identical or similar to SEQ ID NO: 1. The main protein is preferably VWF. The fusion protein has an increased half life as compared to the main protein and may be used to increase the half-life of a binding partner, e.g. FVIII. The invention further relates to the complex formed by the fusion protein, a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.Type: ApplicationFiled: April 26, 2017Publication date: June 6, 2019Applicant: OCTAPHARMA AGInventors: Christoph KANNICHT, Barbara SOLECKA-WITULSKA, Stefan WINGE, Tilo SCHWIENTEK